Quick Answer
NewAmsterdam Pharma Co N.V. reported Net Income of -$203.82 million for fiscal year 2025.
NewAmsterdam Pharma Co N.V. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$203.82M | +15.6% |
| 2024 | -$241.60M | -36.5% |
| 2023 | -$176.94M | -681.7% |
| 2022 | -$22.63M | +45.8% |
| 2021 | -$41.78M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$72.00M | -332.5% | -314.7% |
| June 30, 2025 | -$17.36M | +55.5% | +56.1% |
| March 31, 2025 | -$39.53M | +57.8% | -137.4% |
| September 30, 2024 | -$16.65M | — | +57.3% |
| June 30, 2024 | -$39.01M | -1.9% | +58.4% |
| March 31, 2024 | -$93.77M | -123.2% | -144.9% |
| June 30, 2023 | -$38.29M | — | +8.9% |
| March 31, 2023 | -$42.02M | — | — |
- NewAmsterdam Pharma Co N.V. showed an increase of +15.6% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, NewAmsterdam Pharma Co N.V.’s net income has declined by 387.8% (from -$41.78 million to -$203.82 million).
- The most recent figure is from NewAmsterdam Pharma Co N.V.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: